Therefore, we utilized melanoma immunotherapy studies, in which clinical and gene expression data were obtained from published studies on melanoma patients receiving anti-PD-1 monotherapy, anti-CTLA-4 monotherapy or anti-PD-1/anti-CTLA-4 combined therapy (12–15). This evidence concerns the gene CTLA4 and melanoma.